Department of Nuclear Medicine, Peking University Shenzhen Hospital, Shenzhen, Guangdong, China.
Department of Thyroid and Breast Surgery, Peking University Shenzhen Hospital, Shenzhen, Guangdong, China.
Front Endocrinol (Lausanne). 2023 Mar 13;14:1140888. doi: 10.3389/fendo.2023.1140888. eCollection 2023.
Papillary thyroid cancer (PTC) is a common malignancy of the endocrine system, and its morbidity and mortality are increasing year by year. Traditional two-dimensional culture of cell lines lacks tissue structure and is difficult to reflect the heterogeneity of tumors. The construction of mouse models is inefficient and time-consuming, which is difficult to be applied to individualized treatment on a large scale. Clinically relevant models that recapitulate the biology of their corresponding parental tumors are urgently needed. Based on clinical specimens of PTC, we have successfully established patient-derived organoids by exploring and optimizing the organoid culture system. These organoids have been cultured stably for more than 5 passages and successfully cryopreserved and retried. Histopathological and genome analysis revealed a high consistency of the histological architectures as well as mutational landscapes between the matched tumors and organoids. Here, we present a fully detailed method to derive PTC organoids from clinical specimens. Using this approach, we have developed PTC organoid lines from thyroid cancer samples with a success rate of 77.6% (38/49) until now.
甲状腺乳头状癌(PTC)是内分泌系统常见的恶性肿瘤,其发病率和死亡率逐年上升。传统的细胞系二维培养缺乏组织结构,难以反映肿瘤的异质性。构建小鼠模型效率低、耗时,难以大规模应用于个体化治疗。迫切需要能够重现相应亲本肿瘤生物学特性的临床相关模型。基于 PTC 的临床标本,我们通过探索和优化类器官培养系统,成功建立了患者来源的类器官。这些类器官已经稳定培养了超过 5 代,并成功进行了冷冻保存和重新试验。组织病理学和基因组分析显示,匹配的肿瘤和类器官在组织学结构以及突变景观方面具有高度一致性。在这里,我们提出了一种从临床标本中获得 PTC 类器官的详细方法。使用这种方法,我们已经从甲状腺癌样本中开发出 PTC 类器官系,成功率为 77.6%(38/49)。